New DNA vaccine combo aims to fight hard-to-treat head and neck cancer
NCT ID NCT05280457
First seen Feb 18, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tests a combination of a DNA vaccine (GX-188E), an immune booster (GX-I7), and an immunotherapy drug (nivolumab) in people with advanced head and neck cancer linked to HPV types 16 or 18. The goal is to see if this treatment can shrink tumors or slow the disease. About 21 adults whose cancer worsened after standard chemotherapy will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.